Borderline-Persönlichkeitsstörung

Die Borderline-Persönlichkeitsstörung (BPS) ist eine ernste, aber behandelbare psychische Erkrankung. Psychotherapie ist Behandlung der Wahl, eine psychopharmakologische Behandlung der BPS ist nicht evidenzbasiert. Die Schulung medizinischen Personals in Diagnostik und Behandlung von Patienten mit BPS ist dringend notwendig, um Stigmatisierung zu reduzieren und eine adäquate ambulante Versorgung dieser Patientengruppe zu gewährleisten.

Kernaussagen

• Die BPS geht zumeist mit emotionalem Leid, geringem psychosozialen Funktionsniveau sowie Komorbidität und hohen Krankheitskosten einher.

• Psychotherapie gilt als Behandlung der Wahl und es stehen verschiedene evidenzbasierte psychotherapeutische Therapiemethoden zur Verfügung.

• Für die psychopharmakologische Behandlung gibt es unzureichende Evidenz und Psychopharmaka sollten bei dieser Patientengruppe zurückhaltend eingesetzt werden.

• Um Patienten eine störungsspezifische psychotherapeutische Behandlung zu ermöglichen, ist die Diagnostik und Rückmeldung der BPS-Diagnose unumgänglich. Hierfür ist Schulung des medizinischen Personals essenziell, um Unsicherheiten und Stigmatisierung in Bezug auf die BPS-Diagnose zu reduzieren.

Schlüsselwörter

Diagnosekriterien - Störungsbild - Symptomatik - Komorbidität - Psychotherapie

Publication History

Publication Date:
22 March 2018 (online)

• Literatur

• 1 American Psychiatric Association. Diagnostic and statistical Manual of mental Disorders (DSM-5^®). Washington, DC: American Psychiatric Pub; 2013
• 2 World Health Organization. The ICD-10 Classification of mental and behavioural Disorders: clinical Descriptions and diagnostic Guidelines. Genf: World Health Organization; 1992
• 3 Wittchen HU, Zaudig M, Fydrich T. SKID. Strukturiertes klinisches Interview für DSM-IV. Achse I und II. Handanweisung. Göttingen: Hogrefe; 1997
• 4 Gunderson JG, Stout RL, Shea MT. et al. Interactions of borderline personality disorder and mood disorders over ten years. J Clin Psychiatry 2014; 75: 829
• 5 Bach B, Sellbom M, Skjernov M. et al. ICD-11 and DSM-5 personality trait domains capture categorical personality disorders: Finding a common ground. Aust N Z J Psychiatry 2017;
• 6 Tomko RL, Trull TJ, Wood PK. et al. Characteristics of borderline personality disorder in a community sample: comorbidity, treatment utilization, and general functioning. J Pers Disord 2014; 28: 734-750
• 7 ten Have M, Verheul R, Kaasenbrood A. et al. Prevalence rates of borderline personality disorder symptoms: a study based on the Netherlands Mental Health Survey and Incidence Study-2. BMC Psychiatry 2016; 16: 249
• 8 Wagner T, Fydrich T, Stiglmayr C. et al. Societal cost-of-illness in patients with borderline personality disorder one year before, during and after dialectical behavior therapy in routine outpatient care. Behav Res Ther 2014; 61: 12-22
• 9 Zanarini MC, Frankenburg FR, Dubo ED. et al. Axis I comorbidity of borderline personality disorder. Am J Psychiatry 1998; 155: 1733-1739
• 10 Zanarini MC, Frankenburg FR, Dubo ED. et al. Axis II comorbidity of borderline personality disorder. Compr Psychiatry 1998; 39: 296-302
• 11 McGlashan TH, Grilo CM, Skodol AE. et al. The Collaborative Longitudinal Personality Disorders Study: baseline Axis I/II and II/II diagnostic co-occurrence. Acta Psychiatrica Scand 2000; 102: 256-264
• 12 Barrachina J, Pascual JC, Ferrer M. et al. Axis II comorbidity in borderline personality disorder is influenced by sex, age, and clinical severity. Compr Psychiatry 2011; 52: 725-730
• 13 Silberschmidt A, Lee S, Zanarini M. et al. Gender differences in borderline personality disorder: results from a multinational, clinical trial sample. J Pers Disord 2015; 29: 828-838
• 14 Fok ML, Hayes RD, Chang CK. et al. Life expectancy at birth and all-cause mortality among people with personality disorder. J Psychosom Res 2012; 73: 104-107
• 15 Kahl KG, Greggersen W, Schweiger U. et al. Prevalence of the metabolic syndrome in patients with borderline personality disorder: results from a cross-sectional study. Eur Arch Psychiatry Clin Neurosci 2013; 263: 205-213
• 16 El-Gabalawy R, Katz LY, Sareen J. Comorbidity and associated severity of borderline personality disorder and physical health conditions in a nationally representative sample. Psychosom Med 2010; 72: 641-647
• 17 Frankenburg FR, Zanarini MC. The association between borderline personality disorder and chronic medical illnesses, poor health-related lifestyle choices, and costly forms of health care utilization. J Clin Psychiatry 2004; 65: 1660-1665
• 18 Lam DC, Salkovskis PM, Hogg LI. ‘Judging a book by its cover’: An experimental study of the negative impact of a diagnosis of borderline personality disorder on cliniciansʼ judgements of uncomplicated panic disorder. Br J Clin Psychol 2016; 55: 253-268
• 19 Strauß B. Chancenungleichheit auf der Suche nach einem Therapieplatz. Psychotherapeut 2015; 60: 389-396
• 20 Jobst A, Hörz S, Birkhofer A. et al. Einstellung von Psychotherapeuten gegenüber der Behandlung von Patienten mit Borderline Persönlichkeitsstörung. PPmP-Psychother Psychosom Med Psychol 2010; 60: 126-131
• 21 Keuroghlian AS, Palmer BA, Choi-Kain LW. et al. The effect of attending good psychiatric management (GPM) workshops on attitudes toward patients with borderline personality disorder. J Pers Disord 2016; 30: 567-576
• 22 Knaak S, Szeto ACh, Fitch K. et al. Stigma towards borderline personality disorder: effectiveness and generalizability of an anti-stigma program for healthcare providers using a pre-post randomized design. Borderline Personal Disord Emot Dysregul 2015; 2: 9
• 23 Sharp C, Fonagy P. Practitioner Review: Borderline personality disorder in adolescence–recent conceptualization, intervention, and implications for clinical practice. J Child Psychol Psychiatry 2015; 56: 1266-1288
• 24 Griffiths M. Validity, utility, and acceptability of borderline personality disorder diagnosis in childhood and adolescence: survey of psychiatrists. The Psychiatrist 2011; 35: 19-22
• 25 Zanarini MC, Horwood J, Wolke D. et al. Prevalence of DSM-IV borderline personality disorder in two community samples: 6,330 English 11-year-olds and 34,653 American adults. J Pers Disord 2011; 25: 607-619
• 26 Zanarini MC, Temes CM, Magni LR. et al. Prevalence rates of borderline symptoms reported by adolescent inpatients with BPD, psychiatrically healthy adolescents and adult inpatients with BPD. Personal Ment Health 2017; 11: 150-156
• 27 Merza K, Papp G, Kuritárné Szabó I. The role of childhood traumatization in the development of borderline personality disorder in Hungary. Eur J Psychiatry 2015; 29: 105-118
• 28 Gunderson JG, Zanarini MC, Choi-Kain LW. et al. Family study of borderline personality disorder and its sectors of psychopathology. Arch Gen Psychiatry 2011; 68: 753-762
• 29 Amad A, Ramoz N, Thomas P. et al. Genetics of borderline personality disorder: systematic review and proposal of an integrative model. Neurosci Biobehav Rev 2014; 40: 6-19
• 30 Witt SH, Streit F, Jungkunz M. et al. Genome-wide association study of borderline personality disorder reveals genetic overlap with bipolar disorder, major depression and schizophrenia. Transl Psychiatry 2017; 7: e1155
• 31 Fiedler P, Herpertz S. Persönlichkeitsstörungen. Weinheim: Beltz Verlag; 2016
• 32 Zanarini MC, Frankenburg FR, Reich DB. et al. Attainment and stability of sustained symptomatic remission and recovery among patients with borderline personality disorder and axis II comparison subjects: a 16-year prospective follow-up study. Am J Psychiatry 2012; 169: 476-483
• 33 Zanarini MC, Frankenburg FR, Reich DB. et al. Fluidity of the subsyndromal phenomenology of borderline personality disorder over 16 years of prospective follow-up. Am J Psychiatry 2016; 173: 688-694
• 34 Choi-Kain LW, Finch EF, Masland SR. et al. What works in the treatment of borderline personality disorder. Curr Behav Neurosci Reports 2017; 4: 21-30
• 35 Cristea IA, Gentili C, Cotet CD. et al. Efficacy of psychotherapies for borderline personality disorder: A systematic review and meta-analysis. JAMA Psychiatry 2017; 74: 319-328
• 36 Bateman AW, Fonagy P. Handbuch Mentalisieren. Gießen: Psychosozial-Verlag; 2014
• 37 Clarkin JF, Yeomans FE, Kernberg OF. Psychotherapie der Borderline-Persönlichkeit. Stuttgart: Schattauer; 2008
• 38 Bohus M, Wolf-Arehult M. Interaktives Skillstraining für Borderline-Patienten. Stuttgart: Schattauer; 2012
• 39 Linehan M. DBT. Handbuch beide Bände. München: CIP-Medien; 2016
• 40 Arntz A, van Genderen H, Schweiger U. Schematherapie bei Borderline-Persönlichkeitsstörung. Weinheim: Beltz; 2010
• 41 Stoffers J, Völlm BA, Rücker G. et al. Pharmacological interventions for borderline personality disorder. Cochrane Database Syst Rev 2010; (06) CD005653
• 42 Lieb K, Völlm B, Rücker G. et al. Pharmacotherapy for borderline personality disorder. Br J Psychiatry 2010; 196: 4-12
• 43 Chanen AM, Thompson KN. Prescribing and borderline personality disorder. Australian Prescriber 2016; 39: 49
• 44 Rief W, Barsky A, Bingel U. et al. Rethinking psychopharmacotherapy: the role of treatment context and brain plasticity in antidepressant and antipsychotic interventions. Neurosci Biobehavl Rev 2016; 60: 51-64
• 45 Zanarini MC, Frankenburg FR, Hennen J. et al. Mental health service utilization by borderline personality disorder patients and Axis II comparison subjects followed prospectively for 6 years. J Clin Psychiatry 2004; 65: 28-36